How ADC Target Nanobody Discovery Works: From Target Assessment to Candidate Evaluation

ADC target nanobody discovery is a staged process: define a suitable cell-surface target, generate nanobodies that bind it, and evaluate whether promising binders have properties compatible with antibody–drug conjugate development. Binding alone is not enough. We also consider target distribution, cellular uptake, internalization, specificity, and the practical requirements of downstream conjugation and testing. At NBbiolab, we work with project teams to align discovery plans with their target, intended application, and evaluation criteria, including veterinary medicine programs.

Click here to get more.

A nanobody, often based on a camelid VHH domain, is a compact antibody-derived binding format. A VHH domain is commonly described as approximately 12–15 kDa and around 110–130 amino acids; these are general format ranges, not specifications for every candidate. For an ADC program, the central question is whether a candidate can bind an appropriate target and support the biological and developability requirements of the intended construct.

Summary of the Discovery Workflow

• Assess target biology, cell-surface accessibility, expression patterns, and project-specific risks before selecting a discovery strategy.
• Generate or source a suitable nanobody repertoire, then enrich and screen candidates for binding to the intended target.
• Evaluate specificity, cell binding, internalization, developability, and cross-reactivity where relevant to the program.
• Advance candidates based on a defined evidence package, while treating ADC performance as a property of the complete construct rather than the binder alone.

Step 1: Assess the Target and Define the Goal

We begin by clarifying what the project is trying to achieve. The target should generally be accessible on the cell surface, and its expression pattern should be considered in the intended disease and species context. For veterinary medicine, this means defining whether the program is aimed at a particular animal species, a comparative oncology model, or a target intended to support more than one species.

Review target biology and evidence

Before discovery starts, buyers should gather available evidence on target expression, cellular location, biological function, and normal-tissue distribution. We also recommend documenting the intended indication, target species, available positive and negative cell models, and any known target sequence differences. These inputs help determine which antigens and assays are appropriate and reduce the risk of selecting binders against a form of the target that does not reflect the intended application.

Target expression does not by itself prove that an ADC will work. The project should also consider whether binding can lead to internalization and whether the target may reach intracellular compartments compatible with the chosen payload and linker strategy. These questions are typically evaluated experimentally; they should not be assumed from target identity alone.

Step 2: Choose the Discovery Strategy and Antigen

Once the target and use case are defined, the discovery team selects an antigen format and a source of nanobody diversity. Antigens may include purified target domains, full-length proteins presented in a membrane-like context, or target-expressing cells. Each format has trade-offs: purified proteins can support controlled selection, while cell-based formats can help preserve features associated with the native cell surface.

Match the antigen to the biological question

We recommend confirming that the antigen represents the relevant target species and domain, and checking whether its preparation could affect key binding regions. If the program depends on recognition of native target on cells, a cell-based binding assay should be included rather than relying only on purified-protein binding. When veterinary and human targets differ, teams should decide early whether they need species-specific candidates or cross-reactive binders.

Discovery may use an immune repertoire or a synthetic or naïve library, depending on project design and available materials. The appropriate route depends on the target, schedule, desired diversity, and whether immunization is suitable. No strategy guarantees a functional ADC binder, so selection and screening criteria should be agreed before work begins.

Step 3: Enrich and Screen Nanobody Candidates

During selection, the repertoire is exposed to the chosen antigen or target-expressing cells, and binders are enriched through repeated rounds of screening or panning. Counter-selection can be used to reduce binding to irrelevant proteins, assay components, or related targets. The exact workflow depends on antigen format and project objectives, so round counts and operating conditions should be established by the discovery team rather than treated as universal settings.

For more information, please visit NBbiolab.

Enriched candidates are then assessed in follow-up assays. Initial tests may measure binding to the target, while confirmatory tests examine binding to cells that express the target and compare them with appropriate negative controls. Where available, sequence analysis can identify unique candidates and related sequence families, helping teams avoid advancing several near-identical binders without a clear reason.

Step 4: Evaluate ADC-Relevant Properties

Candidate evaluation should move beyond affinity or a positive binding signal. The team should ask whether binding is specific, whether it occurs on the intended cell type, and whether the candidate internalizes under the conditions relevant to the program. If internalization is a key requirement, it should be measured directly with a suitable assay and interpreted alongside target expression and assay design.

Assess specificity, cross-reactivity, and developability

Specificity testing can include target-negative cells, related proteins, or other controls selected for the target family. Cross-reactivity may be important when the ADC is intended for veterinary use or when a species-matched model is needed for later evaluation. A candidate that binds one species’ target should not be assumed to bind another species’ ortholog without testing.

Developability assessment may include sequence review, expression and purification behavior, solubility, stability, and aggregation risk. These properties can influence whether a nanobody is practical to produce and modify, but results are construct- and process-dependent. ADC design also involves linker, payload, conjugation method, and drug-to-antibody ratio; DAR values are often explored across a range such as 2–8, but the suitable value depends on the specific molecule and development strategy.

Key Decision Points and Common Mistakes

A key decision is whether to prioritize the strongest measured binder or the candidate with the best overall profile. High affinity can be useful, but it does not establish cell-surface accessibility, internalization, selectivity, or conjugate performance. Advancement criteria should therefore combine binding data with the biological and manufacturing requirements of the project.

• Choosing an unsuitable antigen: A purified fragment may not represent the native target conformation or cell-surface presentation.
• Relying on one assay: A single binding result cannot establish specificity, internalization, or suitability for conjugation.
• Ignoring species differences: Veterinary programs should confirm binding to the intended species target and relevant model systems.
• Assuming the binder predicts ADC efficacy: The final conjugate’s behavior depends on the complete construct, including linker and payload choices.

How to Optimize the Project and Select a Supplier

Buyers can improve project alignment by sharing target sequence information, species requirements, intended indication, available cell lines, and the planned downstream format. It is also useful to specify which outputs are needed, such as candidate sequences, binding data, cell-based results, or material for additional evaluation. Agreeing on acceptance criteria and decision gates before discovery helps make candidate comparisons more meaningful.

When evaluating a supplier, ask how the team will select the antigen format, manage counter-selection, confirm cell binding, and report sequence-level results. Clarify which assays are included, which are optional, what material will be delivered, and whether conjugation or ADC characterization is within the project scope. At NBbiolab, we can discuss a custom nanobody discovery plan around these requirements and identify which questions belong in discovery versus downstream ADC evaluation.

Conclusion: From Target Assessment to a Better-Informed Candidate Decision

ADC target nanobody discovery works best as a decision-led workflow, beginning with target suitability and ending with a balanced assessment of candidate biology and developability. The most useful candidate is not simply the one with a binding signal; it is the one supported by evidence relevant to the target, species, cell model, and intended conjugate. For veterinary medicine projects, early attention to species-specific binding and model selection is especially important.

As a next step, prepare a target brief covering the sequence, species, expression evidence, intended application, available assays, and desired deliverables. NBbiolab can use that information to discuss a fit-for-purpose discovery and evaluation plan, including the decision points that should be resolved before candidate nomination. Contact our team to review your ADC target nanobody discovery requirements and define a practical project scope.